Non-Invasive Body Contouring Patents: Who Leads, Trends 2026
- Concentrated at the top. The five leading assignees hold 196 of 279 records in scope (70.3%), and the top ten hold 87.1% — a field with little room left for a new entrant to build a broad position.
- Filing has kept climbing, not flattened. Filings rose from 11 in 2021 to 14 in 2024, a 27% increase over that three-year span, even as the two most recent years understate true activity due to publication lag.
- Claims cluster in three overlapping classes. A61F, A61N and A61B each cover roughly 44-50% of the 279 records, meaning most filings stake claims across implant/prosthesis, electrotherapy and diagnostic-surgical categories at once.
Filing growth compares 2021 (11 records) with 2024 (14) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 279 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This review maps 279 published patent records filed between 2015 and mid-2026 that combine body-contouring or fat-reduction concepts — cryolipolysis, fat reduction devices — with specific engineering claims around applicator design, cooling intensity, treatment cycles, paradoxical hyperplasia management, fat layer thickness sensing, or patient comfort. It is a claims-level view of how device makers have tried to own the mechanics of non-surgical fat and skin treatment, not a market-share study.
Records span receiving offices from the United States through WIPO, Europe, Israel, Australia and Singapore, reflecting a field where filing strategy is genuinely international rather than concentrated in one jurisdiction.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 279 records: how filing volume has moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017-2026
Filings peaked at 30 in 2019, held in the low-to-mid teens through the early 2020s, and reached 14 in 2024 — up 27% from 11 in 2021. The 2025-2026 figures (down to 5 in the partial latest year) reflect publication lag of roughly 18 months rather than a real slowdown in filing.
Technology composition by IPC subclass
A61F (implants and prostheses) appears on 49.8% of the 279 records, A61N (electrotherapy and radiation) on 45.2%, and A61B (diagnosis and surgery) on 44.1% — the three overlap heavily, since a single applicator patent commonly claims a physical structure, an energy-delivery mechanism and a diagnostic or procedural step together. Cosmetics-use claims under A61Q sit at just 2.5%, and body-fluid device claims under A61M at 1.4%, marking the thinnest-claimed corners of the field.
Shares are the percentage of the 279 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Non-Invasive Body Contouring with Eureka
This page is one run against one query. Ask Eureka your own question about non-invasive body contouring and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited records
US10864305B2 — Skin treatment using variable RF
A skin treatment device used for cellulite treatment, skin tightening or body contouring which combines negative pressure treatment and RF treatment, where the RF treatment uses variable frequencies during a treatment cycle.Filed by Viora Ltd., granted 2020-12-15 — illustrates the pattern of combining a mechanical delivery mode (negative pressure) with a variable-frequency energy claim inside a single treatment-cycle architecture.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20200061385A1 | Aesthetic method of biological structure treatment by magnetic field | 312 |
| 2 | US20140277302A1 | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same | 216 |
| 3 | US20100280582A1 | Device, system and method of removing heat from subcutaneous lipid-rich cells | 208 |
| 4 | US20150216719A1 | Treatment systems and methods for treating cellulite and for providing other treatments | 207 |
| 5 | US20120226214A1 | Devices and methods for skin tightening | 190 |
| 6 | US8702774B2 | Device, system and method of removing heat from subcutaneous lipid-rich cells | 165 |
| 7 | US20180236254A1 | Aesthetic Method of Biological Structure Treatment by Magnetic Field | 135 |
| 8 | US20170325992A1 | Skin freezing systems for treating acne and skin conditions | 130 |
| 9 | US20170326346A1 | Permeation enhancers and methods of cryotherapy | 113 |
| 10 | US20130123629A1 | Method and apparatus for measuring the thickness of adipose tissue | 113 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus; treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns worth acting on before drafting a new application in this space.
The top of the field is crowded, not the whole field
With five assignees controlling 70.3% of the 279 records in scope and ten controlling 87.1%, broad applicator or cooling-cycle claims are heavily pre-empted. The remaining assignees among the 77 ranked hold thin, often single-filing positions — useful for freedom-to-operate checks but not for benchmarking a broad strategy.
Growth is real once lag is accounted for
Filings rose from 11 in 2021 to 14 in 2024, a 27% increase, even though the peak year on record remains 2019 at 30. The drop-off visible in 2025-2026 in the raw counts is an artefact of the roughly 18-month gap between filing and publication, not a genuine cooling of interest.
Claims stack across mechanical, energy and procedural categories
The three largest IPC subclasses — A61F, A61N and A61B — each cover close to or above 44% of the 279 records, and because a record can carry multiple classes these shares overlap substantially. A single competitive filing typically has to clear structural, energy-delivery and procedural prior art simultaneously.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to non-invasive body contouring, with the prior art for and against each one.
Who holds the ground, and where it is thin
Recent-year momentum shows the leaders are not filing at the same pace as their historical share would suggest.
One assignee sets the scale for the field
The leading assignee's 86 records dwarf the fifth-place figure of 11 and the tenth-place figure of 8, meaning the concentration in this field is driven substantially by a single very large portfolio rather than an even spread across the top ten.
Even leaders show flat or falling recent-year activity
Recent-year momentum among the tracked leading assignees ranges from flat (0% YoY) to a full pull-back (-100% YoY), which lines up with the broader publication-lag effect rather than signalling that the leaders have exited the space.
Co-filing is limited and concentrated around one assignee
Only 10 co-assignee pairs appear in the dataset, and the strongest recurring pairings all involve the same leading corporate assignee working with named inventors — a pattern of internal inventor credit rather than cross-company joint filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Cynosure, Inc. | 1 | 0% |
| ZELTIQ Aesthetics, Inc. | 0 | -100% |
| BTL MEDICAL TECH SRO | 0 | — |
| BTL Medical Technologies s.r.o. | 0 | -100% |
| DASYO TECH LTD | 0 | — |
| The General Hospital Corporation | 0 | — |
| BTL Medical Solutions a.s. | 0 | — |
| MEDICAL TECH CZ A S | 0 | — |
Where to take this next
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, white space discovery, or competitive tracking.
Check freedom-to-operate against the leader's portfolio
With one assignee holding 86 of 279 records, any new applicator or cooling-cycle filing should be checked against that single portfolio first, before surveying the long tail of single-filing entrants.
Run an FTO screen in EurekaProbe the under-claimed branches directly
A61Q cosmetics-use claims and A61M body-fluid claims sit at 2.5% and 1.4% of records respectively — thin enough to warrant a targeted prior-art search before assuming the space is open.
Explore white space in EurekaTrack momentum, not just historical share
Recent-year YoY figures for the tracked leaders range from flat to a full pull-back, which changes who to watch relative to the historical top-5 ranking.
Set up assignee monitoring in EurekaCommon questions on this landscape
One assignee leads the field with 86 of the 279 records in scope, well ahead of the fifth-ranked assignee at 11 and the tenth-ranked at 8. The top five assignees together hold 196 records, or 70.3% of the total, and the top ten hold 87.1%. This means the field is dominated by a small number of large portfolios rather than being evenly spread, so any competitive or freedom-to-operate review should start with the leader's filings specifically.
Yes, based on the most recent complete data: filings rose from 11 in 2021 to 14 in 2024, a 27% increase over that span. The historical peak was higher, at 30 filings in 2019, so growth has not returned to that level, but the trend from 2021 to 2024 is upward, not flat. The lower counts shown for 2025 and 2026 reflect the roughly 18-month lag between filing and publication and should not be read as declining interest.
The claims cluster heavily around three IPC subclasses: A61F (implants and prostheses) at 49.8% of the 279 records, A61N (electrotherapy and radiation therapy) at 45.2%, and A61B (diagnosis and surgery) at 44.1%. Because a single patent can carry multiple IPC classes, these figures overlap substantially — a typical filing claims a physical applicator structure, an energy-delivery mechanism, and a procedural or diagnostic step together. Smaller shares of records touch A61K medicinal preparations, A61H physical therapy, A61P therapeutic activity, A61Q cosmetics use, and A61M body-fluid devices.
The thinnest-claimed corners of this dataset are cosmetics-use claims under A61Q, at 2.5% of the 279 records, and body-fluid device claims under A61M, at just 1.4%. Paradoxical hyperplasia mitigation and fat-layer-thickness sensing also appear as narrower, less-crowded branches relative to the core applicator and cooling-cycle claims that dominate the top three IPC classes. These are the areas worth a targeted prior-art search before assuming broad claim space is closed, though thin coverage does not guarantee patentability — it only means fewer existing claims to design around.
US10864305B2, assigned to Viora Ltd. and granted in December 2020, covers a skin treatment device that combines negative-pressure treatment with RF treatment, where the RF frequency varies during the treatment cycle. It sits within the same claim territory as the field's most-cited records, which also center on fluid-cooled or energy-delivery applicators for fat and skin treatment. A new RF applicator design would need to differentiate on the specific combination of delivery mode and frequency-variation method to avoid overlap with this and the field's other highly cited prior art.
Research Non-Invasive Body Contouring in depth with Eureka
Go past this page: query the whole non-invasive body contouring corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.